Dr. Mark G. Kris Describes Pan-HER Inhibition in Lung Cancer

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, explains that HER-binding combinations produce differences in cancer cells. The HER1 protein works by binding to other HER proteins and can be inhibited. Pan-HER inhibiting agents are in development to block several HER proteins simultaneously and fight cancer cells more effectively. Dacomitinib and afatinib are small-molecule inhibitors and bind to the HER1 receptor irreversibly.